Aktis Oncology (NASDAQ:AKTS) Shares Down 8.2% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s stock price dropped 8.2% during trading on Friday . The company traded as low as $28.85 and last traded at $28.60. Approximately 457,848 shares changed hands during mid-day trading, an increase of 45% from the average session volume of 315,832 shares. The stock had previously closed at $31.15.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Raymond James Financial started coverage on Aktis Oncology in a report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective for the company. William Blair assumed coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday. Finally, HC Wainwright boosted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Price Performance

The business has a 50 day moving average price of $20.67.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The business had revenue of $1.87 million for the quarter. Equities analysts forecast that Aktis Oncology will post -1.62 earnings per share for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.